

## Preliminary Scientific Program

### Basic Research, Molecular Biology

---

Role of  $\beta$ -adrenoceptor blockade in myocardial induced subcellular remodeling  
**Naranjan S. Dhalla**, Winnipeg, Manitoba, Canada

Gender differences in cardiac ischemic injury and protection  
**Bohuslav Ostadal**, Academy of Sciences of the Czech Republic, Prague, Czech Republic

Role of methionine sulfoxide reductase A (MsrA) in cardiac function  
**Howard Prentice**, College of Biomedical Science, Florida Atlantic University, Boca Raton FL, USA

A Role for GRK2 as a Modulator of Cardioprotective Signalling Pathways  
**Federico Mayor Jr.**, Universidad Autonoma, Madrid, Spain

Intracoronary MRI  
**Xiaoming Yang**, University of Washington School of Medicine, Seattle, WA, USA

Assessing Bioscale of Myocardial Oxygen Metabolism with MRI: Coronary Artery Disease and Beyond  
**Jie Zheng**, Washington University School of Medicine, St Louis, MI, USA

### Stem Cell Research, Myocardial Repair

---

Role of Autologous Stem Cell Therapy in Advanced Heart Diseases  
**Bodo Strauer**, Heinrich-Heine-University, Dusseldorf, Germany

Stem Cells in the Treatment of Coronary Heart Disease and Heart Failure in Humans  
**James T. Willerson**, Univ. of Texas Medical School, Houston, TX, USA

The Fate of Intramyocardial Transplanted Mesenchymal Stem Cells: Angiogenesis or Myogenesis?  
**Keith A. Horvath**, National Heart, Lung and Blood Institute, Bethesda MD, USA

New Approaches for Infarct Repair  
**Jonathan Leor**, Sheba Medical Center, Tel Hashomer, Israel

A Synthetic Molecule for Targeting Infarcted Hearts Towards Cardiovascular Repair  
**Carlo Ventura**, University of Bologna, Bologna, Italy

The Multi-Faceted Contribution of Blood-Derived Progenitors in Atherosclerotic Development or Prevention  
**Gian Paolo Fadini**, University of Padova, Medical School, Padova, Italy

Circulating Cells - Markers and Effectors in Cardiovascular Medicine  
**Imo Hofer**, University Medical Center, Utrecht, Netherlands

Evidence for Cardiac Regeneration after Ischemia-Reperfusion Injury  
**Christer Sylvén**, Karolinska University Hospital, Stockholm, Sweden

Bench to Bedside: NHLBI's Efforts in Gene and Cell Therapies  
**Sonia Skarlatos**, Deputy Director, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD, USA

### **Vascular Biology**

---

Endothelial Dysfunction in Insulin Resistance: Inflammatory Mechanisms  
**Joseph A. Vita**, Boston Medical Center, Boston, MA, USA

Role of Genetic Polymorphisms in Coronary Microvasculature Dysfunction  
**Francesco Fedele**, Sapienza University of Rome, Italy

From Morphology to Coronary Physiology  
**Petr Kala**, BRNO, Czech Republic

Endothelial Progenitor Cells in Cardiovascular Medicine  
**Jacob George**, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

### **Atherogenesis and Atherosclerosis**

---

Macrophages Deposit Cholesterol in the Extracellular Space  
**Howard S. Kruth**, National Heart Lung and Blood Institute, Bethesda, MD, USA

Subclinical Atherosclerosis and Risk Assessment - Coronary Calcium, IMT and ABI  
**Raimund Erbel**, Medizinische Klinik und Poliklinik, Essen, Germany

Immune Modulation of Atherosclerosis Using a Peptide-Based Vaccine  
**Prediman K. Shah**, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Herpes Simplex Virus Type 1 in Brain and Alzheimer's Disease: Potential for Antiviral Treatment, & Possible Implications for Atherosclerotic Disease  
**Ruth F. Itzhaki**, Faculty of Life Sciences, University of Manchester, Manchester, UK

HSP60, TNF and Cardiovascular Disease: A Vicious Circle  
**Anne A. Knowlton**, University of California Davis, Sacramento CA, USA

### **Epidemiology and Prevention**

---

Coronary Heart Disease in Familial Hypercholesterolemia  
**Andrzej Rynkiewicz**, Medical University of Gdansk, Gdansk, Poland

An Update on Alcohol and Cardiovascular Disease  
**R. Curtis Ellison**, Boston University School of Medicine, Boston MA, USA

Biomarkers of Cardiovascular Risk

**Juan Carlos Kaski**, St. George's Hospital Medical School, London, UK

Aspirin in Primary Prevention 2011 - Is There Still a Role, and Who Should Receive It?

**Eli Lev**, Rabin Medical Center and Tel Aviv University, Tel Aviv, Israel

Cardiovascular Diseases in Turkey: Focus on Prevention

**Cetin Erol**, Ankara University, Ankara, Turkey

Efficacy of Multifactorial Treatment of Diabetes Mellitus Type 2, Dyslipidemia and Arterial Hypertension in elderly patients for the prevention of complications and vascular dysfunction

**Nodar Kipshidze**, Institute of Therapy, Tbilisi, Republic of Georgia

### **Acute Coronary Syndromes, Acute Myocardial Infarction**

---

Universal Definition of Myocardial Infarction - a 2011 Update

**Joseph S. Alpert**, University of Arizona Health Sciences Center, Tucson, AZ, USA

Effect of Previous Treatments on Presentation and Course of Acute Coronary Syndromes

**Giuseppe Ambrosio**, University of Perugia School of Medicine, Perugia, Italy

False Positives for STEMI within a Primary PCI Network

**Giuseppe Di Pasquale**, Ospedale Maggiore, Bologna, Italy

Acute myocardial infarction in the young - current opinion

**Igor Riecansky**, Slovak Institute of Cardiovascular Diseases, Bratislava, Slovakia

Pregnancy related Acute Myocardial Infarction - An Update

**Uri Elkayam**, University of Southern California, Los Angeles CA, USA

Milestones in Acute Myocardial Infarction

**Mervyn S. Gotsman**, Hadassah University Hospital, Jerusalem, Israel

Tako-Tsubo Cardiomyopathy - What do we Know and Where do we Stand?

**John D. Horowitz**, University of Adelaide, Adelaide, Australia

### **Clinical Aspects, Ischemia, Hibernation**

---

Hibernating Myocardium: Integrated Diagnostic Testing for Clinical Care

**Shahbudin H. Rahimtoola**, University of Southern California, Los Angeles, CA, USA

Heart Rate - What Role in CHD Management in 2011?

**Sandeep Gupta**, Whipp's Cross and Bartholomew's Hospitals, London, UK

Role of Cardiopulmonary Exercise Testing in Evaluation of Patients with Complex Cardiovascular Disease and Co-Morbidities

**Thomas G. Allison**, Mayo Clinic, Rochester, MN, USA

## Pharmacotherapy

---

Optimal Medical Therapy for Optimal Healing after Myocardial Infarction; How Close Are We?

**Bodh Jugdutt**, University of Alberta Hospitals, Edmonton, Canada

Platelet P2Y<sub>12</sub> receptor Inhibitors in ACS and PCI: Pharmacogenetic and drug-drug interactions

**Maddalena Lettino**, Fondazione IRCCS Policlinico S.Matteo, Pavia, Italy

Heart Rate Slowing for Heart Failure Due to Coronary Artery Disease: Does it Work?

**Jeffrey S. Borer**, New York (SUNY) Downstate Medical Center and SUNY Downstate College of Medicine, New York NY, USA

## New Diagnostic and Imaging Techniques

---

Cardiac CTA: 2011 Update on Clinical Applications and Outcomes

**Andre Duerinckx**, Maplewood Imaging Center, Winston-Salem, NC, USA

The RADICAL trial and New Insights into Non-Calcified Plaque and Radiation Burden

**Avijit Lahiri**, Wellington Hospital, London, UK

Coronary Plaques on 64 Slice CT Angiography in Asymptomatic Diabetics. Can They Predict Late Outcomes?

**David A. Halon**, Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Haifa, Israel

Identifying Patients with Diabetes at High Risk for CAD

**Frans J.Th. Wackers**, Yale University, School of Medicine, New Haven, CT, USA

Recent Developments in Quantitative Assessment of LV Function by Echocardiography Using Speckle Tracking Imaging

**Zvi Vered**, Assaf Harofeh Medical Center, Zerifin, Israel

## Heart Failure and Ventricular Function

---

Myocardial Remodeling

**Dennis V. Cokkinos**, Onassis Cardiac Surgery Center, Athens, Greece

Potential Role of Renin Inhibitors and Aldosterone Blockade in CAD

**Bertram Pitt**, University of Michigan School of Medicine, Ann Arbor, MI, USA

Molecular Remodeling of the Dystrophin-Glycoprotein Complex in Doxorubicin-Induced Cardiomyopathy

**Marcos A. Rossi**, Faculty of Medicine of Ribeirao Preto, Ribeirao Preto, SP, Brazil

Cardiac Allograft Vasculopathy: New Therapeutic Approaches

Sudhir Kushwaha, Mayo Clinic, Rochester, MN, USA

## **Interventional Cardiology**

---

"Stent for Life" Initiative of the EAPCI

**Petr Widimsky**, Cardiocenter Vinohrady, Prague, Czech Republic

PCI for left main coronary artery disease: current status

**Barry F. Uretsky**, University of Arkansas for Medical Sciences, Little Rock AR, USA

Long-Term Safety and Efficacy of Stenting vs. Coronary-Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease : 5-year Results From the MAIN-COMPARE Registry

**Seung-Jung Park**, Seoul, South Korea

Balancing Safety versus Efficacy of DES

**Edoardo Camenzind**, Interventional Cardiology, Geneva, Switzerland

Bio-Eluting Stents - A New Therapeutic Option for Treating Coronary Artery Disease

**Otto M. Hess**, Swiss Cardiovascular Center, Bern, Switzerland

How to Select a Drug Eluting Stent in Diabetic Patients?

**Ran Kornowski**, Rabin Medical Center and Tel Aviv University, Tel Aviv, Israel

Relation of Hemoglobin A1C to Restenosis after PCI

**Itamar Raz**, Hadassah-Hebrew University Hospital, Jerusalem, Israel

Interventional Treatment of Vulnerable Plaque

**Nicholas N. Kipshidze**, Lenox Hill Hospital, New York NY, USA

Atherothromboaspiration: Possible Cure for the No-Reflow Phenomenon

**Antonis S. Manolis**, Evagelismos General Hospital, Athens, Greece

Thrombus Management during PCI

**Chaim Lotan**, Hadassah-Hebrew University Hospital, Jerusalem, Israel

Affordable DES for All?

**Kobi Richter**, Medinol Group, Jerusalem, Israel

Interventional Cardiology in the Third Age

**Morris Mosseri**, Meir Medical Center and Tel Aviv University, Kfar Saba, Israel

Robotics assisted PCI

**Giora Weisz**, Columbia University Medical Center, New York NY, USA

Innovation in Cardiovascular Disease - An Industry-Based Perspective

**Martin T. Rothman**, The London Chest Hospital, London, UK

## **Carotid, Peripheral and Valvular Interventions**

---

Management of concomitant carotid and coronary disease

**Amir Halkin**, Tel Aviv Medical Center, Tel Aviv, Israel

Percutaneous Valve Therapy

**Peter C. Block**, Emory University Hospital, Atlanta, GA, USA

Percutaneous Aortic Core-Valve Implantation (TAVI): Is It Ready for Wider Use?

**Thomas A. Ischinger**, Center for Diabetology & Cardiovascular Medicine, Munchen, Germany

TAVI in Israel 2011

**Haim Danenberg**, Hadassah-Hebrew University Hospital, Jerusalem, Israel

4D CTA Guidance of Paravalvular Leak Closures and Percutaneous Mitral Valve Repair Technologies

**Carlos E. Ruiz**, Lenox Hill Heart and Vascular Institute, New York, NY, USA

Endovascular Treatment of Acute Aortic Dissection

**Christoph A. Nienaber**, University of Münster, Münster, Germany

## **Surgical Aspects**

---

Leonardo da Vinci`s Influence on Modern Heart Valve Therapy - History and Future

**Matthias Overbeck**, University Hospital Salzburg, Salzburg, Austria

Surgical Approach in Treatment of Associated Coronary and Carotid Artery Disease

**Leo A. Bockeria**, Russian Academy of Medical Sciences, Moscow, Russia

The Value of Interventional Mitral Valve Repair in Patients with Ischemic or Functional Mitral Valve Regurgitation

**Hermann Reichenspurner**, Universitätsklinikum Eppendorf, Hamburg, Germany

Treatment of Functional Mitral Regurgitation

**Alfredo Trento**, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Myocardial Regeneration: The Combination of Cells and Assist Device

**Stephen Westaby**, John Radcliffe Hospital, Oxford, UK

Surgical Options for End-Stages of Coronary Artery Disease

**Roland Hetzer**, German Heart Institute, Berlin, Germany